AstraZeneca

Barbara refused to let stigma define her life despite her lung cancer diagnosis, and as a result, early screening led her to curative treatment. Too often, stigma associated with lung cancer prevents people from seeking care, leading to delays in diagnosis that can potentially worsen their prognosis. November is #LungCancerAwarenessMonth and we’re highlighting patient stories that demonstrate the importance of overcoming stigma and empowering others to take control of their health. Tune into Barbara’s story here: https://learn.az/6041sEVrP

Silver Award στα HR Awards 2024 για τον Ψηφιακό Μετασχηματισμό και τη χρήση Τεχνητής Νοημοσύνης και πιο συγκεκριμένα για το πρόγραμμα «ΑΙ Ambassadors». «Η βράβευση αυτή αποτελεί μια σημαντική αναγνώριση των συλλογικών μας προσπαθειών για την ενσωμάτωση της τεχνητής νοημοσύνης και των ψηφιακών εργαλείων στις καθημερινές μας διαδικασίες. Η επένδυση στους ανθρώπους μας και η ανάπτυξη των δεξιοτήτων τους είναι ζωτικής σημασίας για την επιτυχία και τη συνεχή ανάπτυξη του οργανισμού μας», δήλωσε ο Efthymios Nikolopoulos, IBEX & Business Development Director της AstraZeneca Ελλάδας.

We’ve announced our Q3 results, which demonstrate our company continued its growth trajectory in the first nine months of 2024. Given this strong momentum, we have upgraded our Full Year 2024 guidance for Total Revenue and Core EPS to high teens percentage growth. Thank you to our teams around the world who continue to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo

This #Movember, let’s come together to spotlight men’s health and raise awareness about health conditions like #ProstateCancer - the second most common cancer in men globally. Unfortunately, symptoms often do not present in the early stages. By encouraging open and honest conversation on risk factors we can help drive earlier diagnoses and potentially save lives. Join us in supporting men’s health this Movember.

We’ve partnered with experts across the lupus community to launch a new Patient Charter. It calls for higher standards of care to ensure all people living with lupus can access timely, effective, and high-quality care. With updated clinical recommendations prioritising remission as a key goal, now is the time to unite and drive change. Learn more about how we can advance improvements in care: https://learn.az/6043S4pKv

We will share our 9M & Q3 2024 performance update at 07:00 GMT on Tuesday 12 November 2024.        An accompanying webcast for investors and analysts will take place at 2PM GMT – you can register to attend here: https://lnkd.in/esZ5vaY8

We believe empowering the next generation to pursue their interests in science, technology, engineering and mathematics (#STEM) is critical to solve tomorrow’s challenges. Through our global STEM programme, we create and support inclusive and equitable opportunities that inspire students to explore STEM topics and career paths. By uniting with community partners and engaging our employees, we provide a range of engagement and mentorship activities that equip young adults with more tools and opportunities to unlock their potential and drive scientific progress. Learn more about our initiatives: https://learn.az/6045SsAFR #STEMDay

Approximately 60% of patients with severe asthma remain sub-optimally controlled despite treatment with standard-of-care medications. This is in part because inflammation in asthma is complex and heterogeneous, which makes it challenging to manage. We are advancing our understanding of epithelial-driven inflammation, and its implications for patient health and respiratory diseases. Learn more here: https://learn.az/6041SST13

GP's Choice Pharma Company of the Year AstraZeneca was awarded GP's Choice Pharma Company of the Year at the Prime Awards in Sydney last night. This is the fourth year in succession AstraZeneca has won the award voted on by practicing GPs from all over Australia. Thank you to all our wonderful sales and medical field teams for the excellent work you do with GPs to bring life-saving medicines to Australian patients.

Together with Alexion Pharmaceuticals, Inc., we are uniquely positioned to harness the power of genomic insights. Our goal is to advance gene editing technology to unlock new possibilities for managing genetic diseases. Our recent research published in Nature Portfolio demonstrates our progress in refining CRISPR gene editing technology, improving its precision and reliability in editing the DNA sequence. Discover more about how we are engineering the future of gene editing: https://learn.az/6044SsBDk